Prior to 2004, Mr. Thomas served as the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc., a public biopharmaceutical company. Mr. CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on March 11, 2021 at 4:30 p.m. EST to report its fourth quarter and full-year 2020 financial results and provide an update on its business and pipeline. Please go ahead, ma'am. Spero Therapeutics, Inc. (SPRO) Q3 2020 Earnings Call Transcript. The Investor Relations website contains information about Spero Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. Tebipenem HBr advancing towards NDA submission in the second half of 2021. Source: Spero Therapeutics, Inc. Sharon Klahre – Vice President of Investor Relations … Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases. Prior to Ziopharm, Mr. Shukla was Vice President and Global Head of […] ... Vice President, Investor Relations 857-242-1547 Earlier today, Spero Therapeutics released financial results and provided a pipeline update for the third quarter ended September 30, 2020. Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases. Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting. Spero Therapeutics, Inc. ... Vice President of Investor Relations and Strategic Finance. Learn first-hand where Spero Therapeutics is receiving exposure via self-authored articles or other coverage in the biotech trade media, the business press and in the blogosphere. ©2021 Spero Therapeutics All Rights Reserved, Oppenheimer Healthcare Conference – March 16, 2021, Tebipenem HBr: Oral Gram-Negative Program. These forward-looking statements should not be relied upon as representing Spero’s views as of any date subsequent to the date of this press release. Spero Investor and Media Contact: Sharon Klahre Vice President, Investor Relations 857-242-1547 IR@sperotherapeutics.com CAMBRIDGE, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in … Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases. Data Provided by Refinitiv. Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). Sharon Klahre-- Senior Director of Investor Relations… Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2020 Earnings Conference Call March 11, 2021 4:30 PM ET Company Participants. Sath Shukla is Chief Financial Officer at Spero Therapeutics. SPRO Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spero Therapeutics, Inc. and Encourages Investors to Contact the Firm Conference call and live webcast at 4:30 p.m. EST today. Spero Therapeutics, Inc. is regulated by the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants. Spero Therapeutics is looking for a collaborative, enthusiastic leader responsible for the strategic and operational leadership of all investor relations and corporate communications activities for Spero Therapeutics. Spero is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. The audio webcast can be accessed under “Events and Presentations” in the Investor and Media section of the Company’s website at www.sperotherapeutics.com. Minimum 15 minutes delayed. Sharon Klahre is VP:Investor Relations at Spero Therapeutics Inc. See Sharon Klahre's compensation, career history, education, & memberships. Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). Sath Shukla is Chief Financial Officer at Spero Therapeutics. February 24, 2021 – Timmerman Report Comprehensive Policy for Infection: There Has Never Been a Better Time (Blog post authored by Ankit Mahadevia) Spero Investor and Media Contact:Sharon KlahreVice President, Investor Relations857-242-1547IR@sperotherapeutics.com, Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021, ©2021 Spero Therapeutics All Rights Reserved, Tebipenem HBr: Oral Gram-Negative Program. The archived webcast will also be available on Spero’s website for 30 days following the call. These forward-looking statements should not be relied upon as representing Spero’s views as of any date subsequent to the date of this press release. Spero Investor and Media Contact: Sharon Klahre Vice President, Investor Relations 857-242-1547 IR@sperotherapeutics.com Spero Therapeutics, Inc. Condensed Consolidated Statements of … Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securiti In addition to serving as a liaison to the investor community, she provides input on financial strategy […] Investor Relations; Institutional Ownership and Shareholders . These institutions hold a total of 21,358,106 shares. He was most recently Chief Financial Officer at Ziopharm Oncology, Inc., where he directed all of Ziopharm’s financial aspects, including financial planning, analysis and reporting, treasury and tax functions, capital strategy and investor relations. Webcasts of corporate presentations may be accessed through Spero Therapeutics' website (www.sperotherapeutics.com) on the "Events and Presentations" page under the "Investors … Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting. CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive … ... Vice President, Investor Relations 857-242-1547 He was most recently Chief Financial Officer at Ziopharm Oncology, Inc., where he directed all of Ziopharm’s financial aspects, including financial planning, analysis and reporting, treasury and tax functions, capital strategy and investor relations. Sharon Klahre is the Vice President of Investor Relations and Strategic Finance at Spero Therapeutics. He also served on the Board of Directors of Critical Therapeutics from 2006 to 2008. ... Investor Relations… Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for … At this time, I'd like to turn the call over to Sharon Klahre, Vice President of Investor Relations and Strategic Finance. Spero Therapeutics, Inc is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. Sharon Klahre – Senior Director-Investor Relations. In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP. The Investor Relations website contains information about Spero Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. Spero Therapeutics, Inc. (SPRO) Q1 2020 Earnings Call Transcript SPRO earnings call for the period ending March 31, 2020. To access the call, please dial (877) 705-6003 (domestic) or (201) 493-6725 (international) and refer to conference ID 13716494. ... Vice President, Investor Relations 857-242-1547 About Spero Therapeutics Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and … About Spero TherapeuticsSpero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases. Prior to joining Spero Therapeutics in 2017, she led Investor Relations at Forward Pharma A/S, a development stage company focused on multiple sclerosis. Webcasts of the presentations may be accessed through Spero Therapeutics’ website (www.sperotherapeutics.com) on the “Events and Presentations” page under the “Investors … Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases. Sharon Klahre is Director, Investor Relations at Spero Therapeutics, Inc. View Sharon Klahre’s professional profile on Relationship Science, the database of decision makers. In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP. Spero Therapeutics Inc (US:SPRO) has 202 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Spero is also developing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. Spero Investor and Media Contact: Sharon Klahre Senior Director, Investor Relations 857-242-1547 IR@sperotherapeutics.com. For more information, visit https://sperotherapeutics.com. Securities registered pursuant to Section 12(g) of the Act: None .